<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24465901</PMID><DateCompleted><Year>2014</Year><Month>10</Month><Day>29</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>A potential role of myeloid DAP12-associating lectin (MDL)-1 in the regulation of inflammation in rheumatoid arthritis patients.</ArticleTitle><Pagination><StartPage>e86105</StartPage><MedlinePgn>e86105</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e86105</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0086105</ELocationID><Abstract><AbstractText>The pathogenic roles of myeloid DAP12-associating lectin-1(MDL-1) and DAP12 in human rheumatoid arthritis (RA) remain unknown. Frequencies of MDL-1-expressing monocytes in 22 active RA patients, 16 inactive RA patients, 12 osteoarthritis (OA) patients and 10 healthy controls (HC) were determined by flow-cytometry analysis. The mRNA expression levels of MDL-1 and DAP12 on PBMCs were evaluated by quantitative PCR, and their protein expression levels in the synovium were examined by immunohistochemistry. Significantly higher median percentages of circulating MDL-1-expressing monocytes were observed in active RA patients (53.6%) compared to inactive RA patients (34.1%), OA patients (27.9%), and HC (21.2%). Levels of MDL-1 and DAP12 gene expression in PBMCs and their protein expression in the synovium were significantly higher in active RA patients than in inactive RA or OA patients. MDL-1 levels were positively correlated with parameters of disease activity, articular damage, and levels of proinflammatory cytokines. MDL-1 activator (Dengue virus type 2 antigen) stimulation on PBMCs resulted in significantly enhanced levels of proinflammatory cytokines in RA patients compared to those in OA patients or HC, indicating that MDL-1 activation is functional. Frequencies of MDL-1-expressing monocytes and levels of MDL-1 and DAP12 gene expression significantly decreased after effective therapy. Concordant overexpression of MDL-1 and DAP12 were correlated with increased production of proinflammatory cytokines in RA patients, suggesting their roles in regulating articular inflammation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Der-Yuan</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan, R.O.C. ; Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C. ; Institute of Biomedical Science, National Chung-Hsing University, Taichung, Taiwan, R.O.C. ; Institute of Microbiology and Immunology, Chung Shan Medical University, Taichung, Taiwan, R.O.C. ; Infection and Immunity Research Center, National Yang-Ming University, Taipei, Taiwan, R.O.C.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Ling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yi-Ming</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan, R.O.C. ; Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Chi-Chen</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Institute of Biomedical Science, National Chung-Hsing University, Taichung, Taiwan, R.O.C.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Kui-Chou</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Department of Orthopedics and Traumatology, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Szu-Ting</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Infection and Immunity Research Center, National Yang-Ming University, Taipei, Taiwan, R.O.C.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lan</LastName><ForeName>Joung-Liang</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan, R.O.C. ; Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C. ; Division of Immunology and Rheumatology, China Medical University Hospital, Taichung, Taiwan, R.O.C. ; College of Chinese Medicine, China Medical University, Taichung, Taiwan, R.O.C.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Shie-Liang Edmond</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Infection and Immunity Research Center, National Yang-Ming University, Taipei, Taiwan, R.O.C. ; Institute of Clinical Medicine, National Yang-Ming University, Taipei City, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>01</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C509771">CLEC5A protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D037181">Lectins, C-Type</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C110546">TYROBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="N">Arthritis, Rheumatoid</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005434" MajorTopicYN="N">Flow Cytometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018836" MajorTopicYN="N">Inflammation Mediators</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007596" MajorTopicYN="N">Joints</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D037181" MajorTopicYN="N">Lectins, C-Type</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007963" MajorTopicYN="N">Leukocytes, Mononuclear</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010003" MajorTopicYN="N">Osteoarthritis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016133" MajorTopicYN="N">Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011956" MajorTopicYN="N">Receptors, Cell Surface</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013583" MajorTopicYN="N">Synovial Membrane</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24465901</ArticleId><ArticleId IdType="pmc">PMC3897620</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0086105</ArticleId><ArticleId IdType="pii">PONE-D-13-17280</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344: 907&#x2013;916.</Citation><ArticleIdList><ArticleId IdType="pubmed">11259725</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldring SR, Gravallese EM (2000) Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol 12: 195&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">10803748</ArticleId></ArticleIdList></Reference><Reference><Citation>Koga T, Inui M, Inoue K, Kim S, Suematsu A, et al. (2004) Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 428: 758&#x2013;763.</Citation><ArticleIdList><ArticleId IdType="pubmed">15085135</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf3;csai A, Humphrey MB, Van Ziffle JA, Hu Y, Burghardt A, et al. (2004) The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad Sci U S A. 101: 6158&#x2013;6163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC395939</ArticleId><ArticleId IdType="pubmed">15073337</ArticleId></ArticleIdList></Reference><Reference><Citation>Firestein GS (2003) Evolving concepts of rheumatoid arthritis. Nature 423: 356&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pubmed">12748655</ArticleId></ArticleIdList></Reference><Reference><Citation>McInnes IB, Schett G (2007) Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 7: 429&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">17525752</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Bezooijen RL, Van Der Wee-Pals L, Papapoulos SE, Lowik CW (2002) Interleukin 17 synergies with tumor necrosis factor alpha to induce cartilage destruction in vitro. Ann Rheum Dis. 61: 870&#x2013;876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1753923</ArticleId><ArticleId IdType="pubmed">12228154</ArticleId></ArticleIdList></Reference><Reference><Citation>Chabaud M, Lubberts E, Joosten L, van den Berg W, Miossec P (2001) IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res Ther. 3: 168&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC30709</ArticleId><ArticleId IdType="pubmed">11299057</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, et al. (2004) A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis. 63: 1062&#x2013;1068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1755108</ArticleId><ArticleId IdType="pubmed">15082469</ArticleId></ArticleIdList></Reference><Reference><Citation>Yazici Y, Curtis JR, Ince A, Baraf H, Malamet RL, et al. (2012) Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis. 71: 198&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">21949007</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, et al... (2006) Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 54 1063&#x2013;1074.</Citation><ArticleIdList><ArticleId IdType="pubmed">16572441</ArticleId></ArticleIdList></Reference><Reference><Citation>Kievit W, Fransen J, Adang EM, den Broeder AA, Bernelot HJ, et al. (2011) Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch rheumatoid arthritis monitoring register. Rheumatology 50: 196&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">21078625</ArticleId></ArticleIdList></Reference><Reference><Citation>Genovese MC, Van den Bosch F, Roberson SA, Bojin S, Biagini IM, et al. (2010) A humanized anti-IL-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase 1 randomized double-blind, placebo-controlled, proof of concept study. Arthritis Rheum 62: 929&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pubmed">20131262</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao D, Epple H, Uthgenannt B, Novack DV, Faccio R (2006) PLCgamma2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2. J Clin Invest 116: 2869&#x2013;2879.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1616195</ArticleId><ArticleId IdType="pubmed">17053833</ArticleId></ArticleIdList></Reference><Reference><Citation>Takayanagi H (2005) Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med 83: 170&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">15776286</ArticleId></ArticleIdList></Reference><Reference><Citation>Olcese L, Cambiaggi A, Semenzato G, Bottino C, Moretta A, et al. (1997) Human killer cell activatory receptors for MHC class I molecules are included in a multimeric complex expressed by natural killer cells. J Immunol. 158: 5083&#x2013;5086.</Citation><ArticleIdList><ArticleId IdType="pubmed">9164921</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanier LL, Corliss BC, Wu J, Leong C, Phillips JH (1998) Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature 391: 703&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pubmed">9490415</ArticleId></ArticleIdList></Reference><Reference><Citation>Humphrey MB, Ogasawara K, Yao W, Spusta SC, Daws MR, et al. (2004) The signaling adapter protein DAP12 regulates multinucleation during osteoclast development. J Bone Miner Res 19: 224&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">14969392</ArticleId></ArticleIdList></Reference><Reference><Citation>Crotti TN, Dharmapatni AA, Alias E, Zannettino ACW, Smith MD, et al. (2012) The immunoreceptor tyrosine-based activation motif (ITAM)-related factors are increased in synovial tissue and vasculature of rheumatoid joints. Arthritis Res Ther 14: R245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3674611</ArticleId><ArticleId IdType="pubmed">23146195</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker AB, Baker E, Sutherland GR, Phillips JH, Lanier LL (1999) Myeloid DAP12-associated lectin (MDL)-1 is a cell surface receptor involved in the activation of myeloid cells. Proc Natl Acad Sci USA. 96: 9792&#x2013;9796.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22289</ArticleId><ArticleId IdType="pubmed">10449773</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki N, Kimura Y, Kimura S, Nagato T, Azumi M, et al. (2009) Expression and functional role of MDL-1 (CLEC5A) in mouse myeloid lineage cells. J Leukoc Biol. 85: 508&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">19074552</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyce-Shaikh B, Bigler ME, Chao CC, Murphy EE, Blumenschein WM, et al. (2010) Myeloid DAP12-associating lectin (MDL)-1 regulates synovial inflammation and bone erosion associated with autoimmune arthritis. J Exp Med. 207: 579&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2839155</ArticleId><ArticleId IdType="pubmed">20212065</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen ST, Lin YL, Huang MT, Wu MF, Cheng SC, et al. (2008) Lei HY, Lee CK, Chiou TW, Wong CH, Hsieh SL. CLEC5A is critical for dengue-virus-induced lethal disease. Nature 453: 672&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pubmed">18496526</ArticleId></ArticleIdList></Reference><Reference><Citation>Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, et al. (2010) The 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69: 1580&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">20699241</ArticleId></ArticleIdList></Reference><Reference><Citation>Heimans L, Wevers-de Boer KV, Visser K, Goekoop RJ, van Oosterhout M, et al... (2013) A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. Ann Rheum Dis May 28.</Citation><ArticleIdList><ArticleId IdType="pubmed">23716067</ArticleId></ArticleIdList></Reference><Reference><Citation>Prevoo MLL, van&#x2019;t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, et al. (1995) Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 38: 44&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">7818570</ArticleId></ArticleIdList></Reference><Reference><Citation>Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, et al. (2011) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 70: 631&#x2013;637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3015099</ArticleId><ArticleId IdType="pubmed">20215140</ArticleId></ArticleIdList></Reference><Reference><Citation>Genant HK, Jiang Y, Peterfy C, Lu Y, Redei J, et al. (1998) Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs. Arthritis Rheum. 41: 1583&#x2013;1590.</Citation><ArticleIdList><ArticleId IdType="pubmed">9751090</ArticleId></ArticleIdList></Reference><Reference><Citation>Altman R, Asch E, Bloch D, Bole G, Borenstein D, et al. (1986) Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 29: 1039&#x2013;1049.</Citation><ArticleIdList><ArticleId IdType="pubmed">3741515</ArticleId></ArticleIdList></Reference><Reference><Citation>Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162: 156&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">2440339</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson UEM, Heid CA, Williams PM (1996) A novel method for real time quantitative PCR. Genome Res. 6: 995&#x2013;1001.</Citation><ArticleIdList><ArticleId IdType="pubmed">8908519</ArticleId></ArticleIdList></Reference><Reference><Citation>Gingras MC, Lapillonne H, Margolin JF (2001) TREM-1, MDL-1, and DAP12 expression is associated with a mature stage of myeloid development. Mol Immunol. 38: 817&#x2013;824.</Citation><ArticleIdList><ArticleId IdType="pubmed">11922939</ArticleId></ArticleIdList></Reference><Reference><Citation>Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 25: 402&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">11846609</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen DY, Lin CC, Chen YM, Lan JL, Hung WT, et al. (2013) Involvement of TLR7 MyD88-dependent signaling pathway in the pathogenesis of adult-onset Still&#x2019;s disease. Arthritis Res Ther 15: R39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3672755</ArticleId><ArticleId IdType="pubmed">23497717</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang XM, Jiang LF, Tang YX, Yin Y, Liu WQ, et al. (2010) Establishment and characterization of dengue virus type 2 nonstructural protein 1 specific T cell lines. Comp Immunol Microbiol Infect Dis 33: e75&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">20138364</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Cherwinski H, Spies T, Phillips JH, Lanier LL, et al. (2000) DAP10 and DAP12 form distinct, but functionally cooperative, receptor complexes in natural killer cells. J Exp Med 192: 1059&#x2013;1067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2193316</ArticleId><ArticleId IdType="pubmed">11015446</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomasello E, Cant C, Buhring HJ, Vely F, Andre P, et al. (2000) Association of signal-regulatory proteins beta with KARAP/DAP-12. Eur J Immunol 30: 2147&#x2013;2156.</Citation><ArticleIdList><ArticleId IdType="pubmed">10940905</ArticleId></ArticleIdList></Reference><Reference><Citation>Inui M, Kikuchi Y, Aoki N, Endo S, Maeda T, et al. (1999) Signal adaptor DAP10 associates with MDL-1 and triggers osteoclastogenesis in cooperation with DAP12. Proc Natl Acad Sci USA. 106: 4816&#x2013;4821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2660769</ArticleId><ArticleId IdType="pubmed">19251634</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Song Y, Bakker AB, Bauer S, Spies T, et al. (1999) An activating receptor complex on natural killer and T cells formed by NKG2D and DAP10. Science 285: 730&#x2013;732.</Citation><ArticleIdList><ArticleId IdType="pubmed">10426994</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, et al. (2010) An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med. 363: 1303&#x2013;1312.</Citation><ArticleIdList><ArticleId IdType="pubmed">20879879</ArticleId></ArticleIdList></Reference><Reference><Citation>Genovese MC, Kavanaugh A, Weinblatt ME, Peterfy C, DiCarlo J, et al. (2011) An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum. 63: 337&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">21279990</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>